65,437 trials
Falciparum Malaria
Primary: Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose — 14; 10 participants — p=0.17
Osteoporosis
Primary: Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry) — 2.2…
Hidradenitis Suppurativa
Primary: 50% Reduction in Physician's Global Assessment Score (Percent of Participants) — 20 percentage of participants
Gastric Adenocarcinoma · Barrett Esophagus
Primary: Objective Response Rate (ORR) — 3.92 Participants (%)
Meningococcal Infections · Meningitis
Primary: Percentage of Participants With Serum Bactericidal Antibody Titers for Meningococcal Serogroups A, C, Y, and W-135 at ≥ 8 and ≥ 128 at Enrollment — 53; 34; 20; 50…
Hemophilia A
Primary: Initial Recovery — 1.7; 1.6; 1.8 IU/dL per IU/kg — p=0.1662
Upper Respiratory Tract Infections
Primary: Frequency of Influenza-like Illness — 54; 62; 16; 28 participants — p=0.25
Carcinoma, Hepatocellular
Primary: Overall Survival — 198; 127 days — p=0.014144
Hepatitis A · Hepatitis B
Primary: Number of Subjects Seropositive for Anti-hepatitis A Virus Antibodies (Anti-HAV) and Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies and With Anti-HBs Antibody…
Spinal Cord Injury
Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318
Myopia
Primary: Overall Lens Satisfaction — 7.9; 7.9 Units on a Scale
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
HIV Infections
Primary: Summary of Change From Baseline in Alanine Aminotransferase (ALT) to Last Value on Treatment — 1.0 IU/L
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Laryngeal Mask Airway · Tonsillectomy
Primary: Number of Participants With Laryngospasm — 8; 6 Participants